565 studies found for:    Open Studies | "Leukemia, Myeloid, Acute"
Show Display Options
Rank Status Study
21 Not yet recruiting Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cyclophosphamide;   Biological: anti CD123-CAR/CD28-costimulatory, retroviral vector-transduced autologous T lymphocytes;   Other: laboratory biomarker analysis
22 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: filgrastim;   Drug: mitoxantrone hydrochloride;   Drug: cladribine;   Drug: cytarabine
23 Recruiting Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Acute Leukemias of Ambiguous Lineage;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Drug: mitoxantrone hydrochloride;   Drug: etoposide;   Drug: cytarabine;   Other: laboratory biomarker analysis
24 Recruiting Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin hydrochloride;   Drug: vorinostat;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
25 Recruiting Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
26 Unknown  Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
Condition: Leukemia, Myeloid, Acute
Intervention: Procedure: Allogenic transplantation
27 Recruiting AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: HDAC inhibitor AR-42;   Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
28 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
29 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
30 Recruiting Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Intervention: Drug: Oral Azacitidine
31 Recruiting Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Drug: selinexor;   Other: pharmacological study;   Other: laboratory biomarker analysis
32 Recruiting Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
Conditions: Antineoplastic Adverse Reaction;   Thrombocytopenia;   Acute Myelocytic Leukemia
Intervention: Drug: rhTPO
33 Recruiting Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: pomalidomide;   Other: laboratory biomarker analysis
34 Recruiting Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: dasatinib (SPRYCEL);   Drug: all trans retinoic acid (VESANOID)
35 Recruiting Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Interleukin-2
36 Recruiting Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Conditions: Acute Myelogenous Leukemia;   Myelogenous Leukemia;   Treatment Naive AML
Interventions: Drug: ABT-199;   Drug: Decitabine;   Drug: Azacitidine
37 Recruiting Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Preparative Regimen;   Biological: Intravenous Recombinant Human IL-15 (rhIL-15)
38 Recruiting BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BI 836858
39 Recruiting Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Idarubicin
40 Recruiting Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: decitabine iv;   Drug: volasertib iv infusion

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years